Phosphoproteomics

Experimental and Molecular Pathology

Volumn 70, Issue 3, 2001, Pages 327-331

  Stern, David F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEIN; PHOSPHOPROTEOME; PROTEOME; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; GENOME IMPRINTING; HISTOPATHOLOGY; INTERMETHOD COMPARISON; ONCOGENE NEU; PROGNOSIS; PROTEIN PHOSPHORYLATION;

EID: 0034968129     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.2001.2370     Document Type: Article

References (10)

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
2. neu/erbB-2 and the epidermal growth factor receptor
3. Genomic analysis of metastasis reveals an essential role for RhoC
4. Functional assay for HER-2/neu demonstrates active signaling in a minority of HER-2/neu overexpressing invasive human breast tumors
5. neu/erbB-2 in a subset of human breast tumors overexpressing this receptor
6. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor
7. Activation of mitogen-activated protein kinase associated with prostate cancer progression
8. The hallmarks of cancer
9. The biology of erbB-2/neu/HER-2 and its role in cancer
10. Activation (tyrosine phosphorylation) of ErbB-2 (HER2/neu) as a prognostic factor in node positive breast cancer: A study of incidence and correlation with outcome in breast cancer